Low Testosterone: Do You Need TRT or Is There Something to Try First

Testosterone levels mean almost nothing without knowing where the breakdown is happening, and that single piece of context changes everything about what you should actually do.

Your body makes testosterone through a chain that starts in the brain, runs through a gland called the pituitary, and ends at the testicles. The pituitary releases two hormones called LH and FSH, which stands for luteinizing hormone and follicle-stimulating hormone, and these act as the command signal telling your testicles to produce testosterone. When that signal goes out, the testicles respond by producing testosterone, which then feeds back to the brain to regulate how much signal gets sent. It is a loop, not a one-way street.

So when testosterone is low, the question is where in that loop the problem lives.

That is why a testosterone number alone does not tell you very much. A low number tells you the output is wrong. It does not tell you whether the factory stopped getting orders or whether the factory itself stopped being able to fill them. And those two problems have completely different solutions.

You figure out which one you are dealing with by measuring LH and FSH in the same blood draw, ideally in the morning when testosterone is at its daily peak.

If your testosterone is low and your LH and FSH are also low or sitting in the normal range, the problem is at the brain and pituitary level. This is called secondary hypogonadism, which means the signal is not leaving the top of the chain with enough force. Your testicles, in most of these cases, are capable of producing testosterone. They just are not getting the command.

This is the scenario where TRT is often the wrong first move, because TRT adds testosterone from outside the body, which tells the brain the loop is already full, which shuts down whatever natural signaling was still happening, which is the opposite of fixing the underlying problem.

What actually addresses secondary hypogonadism is something that works upstream. One option is clomiphene, which is something called a selective estrogen receptor modulator, or SERM, that works by blocking estrogen's feedback signal at the brain so the pituitary releases more LH and FSH and the testicles get a stronger command. A 2025 systematic review and meta-analysis of 10 randomized controlled trials covering 819 patients found that clomiphene produced a mean testosterone increase of 273.76 ng/dL, which is a meaningful shift without introducing any exogenous hormones and without suppressing natural production or fertility.

The newer version of this, enclomiphene, which is the active isomer of clomiphene, appears to produce the same testosterone-raising effect with a much cleaner side effect profile. A 2024 study in 66 hypogonadal men found that enclomiphene produced a median testosterone increase of 166 ng/dL while generating side effects in only 13.8 percent of patients, compared to 47 percent of patients on standard clomiphene. The mechanism is the same but the tolerability is substantially better.

HCG, which stands for human chorionic gonadotropin and functions essentially as a stand-in for LH, is another option that works by directly stimulating the testicles rather than working at the brain level. Both approaches give the testicles the signal they were not getting on their own.

None of this works, though, if the foundations are not in place first, because poor sleep, nutritional deficits, and sedentary behavior all suppress LH and FSH directly, which means the secondary hypogonadism you are seeing on a lab sheet may not be a dysfunction at all. It may be your body responding accurately to the conditions you are putting it under. No drug addresses that.

Now flip the scenario. If your testosterone is low and your LH and FSH are both high, the picture is completely different. High LH and FSH mean the brain is already sending the signal as loudly as it can. The pituitary is doing its job. The problem is that the testicles are not responding. This is called primary hypogonadism, and in this case, the upstream approach does not work because the signal is already maxed out. Driving more LH into a system that is already ignoring it does not help.

This is the situation where TRT is the appropriate path, because you are replacing what the body genuinely cannot make on its own rather than compensating for a signal problem that could potentially be corrected another way.

The common concern with TRT in men who want to maintain fertility is that exogenous testosterone suppresses the pituitary signal, which reduces sperm production. This is solvable. The Coviello et al. study from 2005 showed that adding HCG at 500 IU every other day was enough to maintain intratesticular testosterone at baseline levels in men whose gonadotropins were otherwise suppressed by exogenous testosterone, meaning the testicles can continue functioning for sperm production even while TRT handles the systemic testosterone level.

The order of operations here is what most conversations about testosterone skip entirely.

Get the LH and FSH alongside the testosterone. If LH and FSH are low or normal with low testosterone, you have a signal problem, and there are effective interventions that work upstream without permanently altering your body's ability to produce testosterone on its own. If LH and FSH are already high, the signal is fine and the production capacity is the issue, which is a different conversation entirely.

Most men who end up on TRT when they did not need it went on it because nobody ran this one additional test or explained what it meant. And most men who stayed off TRT when they should have been on it did so because they kept trying to optimize their way out of a situation where the problem was structural, not lifestyle-driven.

The lab does not tell you what to do, but it tells you exactly where to look, and that is the question that actually needs answering first.

---

References

1. Souza et al. 2025. "Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials." Archives of Endocrinology and Metabolism. 10 RCTs, 819 patients, mean increase 273.76 ng/dL. Source
2. Coviello AD et al. 2005. "Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression." JCEM. 500 IU EOD maintained intratesticular testosterone at baseline. Source
3. Saffati et al. 2024. "Safety and efficacy of enclomiphene and clomiphene for hypogonadal men." Translational Andrology and Urology. 66 men, enclomiphene median increase 166 ng/dL, side effects 13.8% vs 47% with clomiphene. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness